MedTrace Logo

Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy

NCT06980350 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 156

Last updated 2025-07-29

No results posted yet for this study

Summary

A novel evaluation model for identifying complete response following neoadjuvant immune checkpoint inhibitor therapy therapy in patients with dMMR colon cancer was developed to validated its efficacy in two independent cohorts, and to assessed its feasibility for W\&W strategy.

Conditions

Interventions

DRUG

PD-1 Inhibitors

Patients received at least two doses of anti-PD-1 immunotherapy in a neoadjuvant setting.

Sponsors & Collaborators

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • Peirong Ding, M.D. · Sun Yat-sen University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-01
Primary Completion
2023-06-30
Completion
2024-12-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06980350 on ClinicalTrials.gov